| 发明名称 |
Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases |
| 摘要 |
Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed. |
| 申请公布号 |
US2016324846(A1) |
申请公布日期 |
2016.11.10 |
| 申请号 |
US201615152092 |
申请日期 |
2016.05.11 |
| 申请人 |
Vertex Pharmaceuticals Incorporated |
发明人 |
Verwijs Marinus Jacobus;Karkare Radhika;Moore Michael Douglas |
| 分类号 |
A61K31/47;A61K9/14;A61K9/10;A61K9/00;A61K31/443;A61K9/20 |
主分类号 |
A61K31/47 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A pharmaceutical composition comprising a fixed dosage amount of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2). |
| 地址 |
Boston MA US |
